A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 10, 2013, Pages 1453-1458

  Bashir, Qaiser ^a   Khan, Hassan ^b   Thall, Peter F ^a   Liu, Ping ^a   Shah, Nina ^a   Kebriaei, Partow ^a   Parmar, Simrit ^a   Oran, Betul ^a   Ciurea, Stefan ^a   Nieto, Yago ^a   Jones, Roy ^a   Hosing, Chitra M ^a   Popat, Uday R ^a   Dinh, Yvonne T ^a   Rondon, Gabriela ^a   Orlowski, Robert Z ^a   Shah, Jatin J ^a   De Lima, Marcos ^c   Shpall, Elizabeth ^a   Champlin, Richard ^a   Giralt, Sergio ^d   Qazilbash, Muzaffar H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Allogeneic transplantation; Fludarabine; Melphalan; Myeloma; Reduced intensity conditioning

Indexed keywords

FLUDARABINE; MELPHALAN; METHOTREXATE; RITUXIMAB; TACROLIMUS;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CAUSE OF DEATH; DIARRHEA; DISEASE COURSE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; REDUCED INTENSITY CONDITIONING; TREATMENT RESPONSE; VEIN OCCLUSION;

ALLOGENEIC TRANSPLANTATION; FLUDARABINE; MELPHALAN; MYELOMA; REDUCED-INTENSITY CONDITIONING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84884187100     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.008     Document Type: Article

References (56)

1. Bensinger W.I. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?. Best Pract Res Clin Haematol 2007, 20:783-795.
2. Le Blanc R., Montminy-Metivier S., Belanger R., et al. Allogeneic transplantation for multiple myeloma: Further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001, 28:841-848.
3. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. JClin Oncol 2006, 24:929-936.
4. Gahrton G., Iacobelli S., Bandini G., et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007, 92:1513-1518.
5. Kroger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100:755-760.
6. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
7. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
8. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. JClin Oncol 1998, 16:2817-2824.
9. Efebera Y.A., Qureshi S.R., Cole S.M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010, 16:1122-1129.
10. Badros A., Barlogie B., Morris C., et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97:2574-2579.
11. Almeida J., Orfao A., Ocqueteau M., et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999, 107:121-131.
12. Kebriaei P., Saliba R.M., Ma C., et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006, 38:203-209.
13. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
14. Schonland S.O., Lokhorst H., Buzyn A., et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: A report from the European Group for Blood and Marrow Transplantation. Blood 2006, 107:2578-2584.
15. Selvaggi K.J., Wilson J.W., Mills L.E., et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood 1994, 83:1698-1705.
16. Bashir Q., De Lima M.J., McMannis J.D., et al. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 2010, 51:1478-1484.
17. Przepiorka D., Khouri I., Ippoliti C., et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999, 24:763-768.
18. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
19. Parmar S., Del Lima M., Zou Y., et al. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 2009, 114:2884-2887.
20. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
21. Kapoor P., Fonseca R., Rajkumar S.V., et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. Mayo Clinic Proc 2010, 85:532-537.
22. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
23. Thall P.F., Sung H.G. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998, 17:1563-1580.
24. Hosmer D., Lemeshow S. Applied Logistic Regression 2000, John Wiley & Sons, New York. Second Edition.
25. Fischer R. On the interpretation of x2 from contingency tables, and the calculation of P. JRoyal Stat Soc 1922, 85:87-94.
26. Randles R., Wolfe D.A. Introduction to the Theory of Nonparametric Statistics 1979, John Wiley & Sons, New York.
27. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
28. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
29. Cox D.R. Regression models and life tables (with discussion). JRoyal Stat Soc Series B 1972, 34:187-220.
30. Grambsch P., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
31. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. NEngl J Med 2001, 344:1038-1042.
32. Rajkumar S.V. Treatment of multiple myeloma. Nature reviews. Clin Oncol 2011, 8:479-491.
33. Lee C.K., Badros A., Barlogie B., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73-80.
34. Bashir Q., Khan H., Orlowski R.Z., et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012, 87:272-276.
35. Bruno B., Rotta M., Patriarca F., et al. Acomparison of allografting with autografting for newly diagnosed myeloma. NEngland J Med 2007, 356:1110-1120.
36. Bjorkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up. JClin Oncol 2011, 29:3016-3022.
37. Rosinol L., Perez-Simon J.A., Sureda A., et al. Aprospective PETHEMAstudy of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
38. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
39. Lokhorst H.M., van der Holt B., Cornelissen J.J., et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012, 119:6219-6225. quiz 399.
40. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
41. Jimenez-Zepeda V.H., Mikhael J., Winter A., et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012, 18:773-779.
42. Michaelis L.C., Saad A., Zhong X., et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013, 19:760-766.
43. Mehta J., Tricot G., Jagannath S., et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant 1998, 21:887-892.
44. Bensinger W., Rotta M., Storer B., et al. Allo-SCT for multiple myeloma: Areview of outcomes at a single transplant center. Bone Marrow Transplant 2012, 47:1312-1317.
45. Ringden O., Shrestha S., da Silva G.T., et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012, 47:831-837.
46. Kroger N., Perez-Simon J.A., Myint H., et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004, 10:698-708.
47. Schilling G., Hansen T., Shimoni A., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008, 22:1250-1255.
48. Shaughnessy J.D., Zhan F., Burington B.E., et al. Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
49. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEngland J Med 2008, 359:906-917.
50. Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). JClin Oncol 2010, 28:4630-4634.
51. Mateos M.V., Gutierrez N.C., Martin-Ramos M.L., et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 2011, 118:4547-4553.
52. Ayuk F., Perez-Simon J.A., Shimoni A., et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 2008, 93:1343-1350.
53. Kroger N., Shimoni A., Schilling G., et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010, 148:323-331.
54. Knop S., Liebisch P., Hebart H., et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma - an interim analysis of the German DSMM V trial. Blood 2009, 114. Abstract 51.
55. Nivison-Smith I., Dodds A.J., Doocey R., et al. Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: Factors associated with improved survival outcome. Leuk Lymphoma 2011, 52:1727-1735.
56. Shimoni A., Hardan I., Ayuk F., et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: Long-term follow-up. Cancer 2010, 116:3621-3630.